Showing 2231-2240 of 8727 results for "".
New FDA Approval for AD
https://practicaldermatology.com/series/c-suite-chats/new-fda-approval-for-ad/29911/Phil Brown, MD, JD, Dermatologic Scientific Lead at Organon, talks about the importance of a new FDA-approved topical solution for treating atopic dermatitis.Let's Talk About Rosacea and Acne
https://practicaldermatology.com/conferences/scale-2023/acne-and-rosacea/20188/Hilary Baldwin, MD, shares pearls for treating papopustular rosacea, vascular rosacea, and acne.Breaking a Sweat: Treating Hyperhidrosis in the COVID-19 Era
https://practicaldermatology.com/series/dermatology-dispatches/breaking-a-sweat-treating-hyperhidrosis-in-the-covid-19-era/19767/Hyperhidrosis patients can be evaluated with telemedicine, says Neal Bhatia, MD. It’s important that these individuals have adequate supplies of their medication for the duration of any stay-at-home orders. In addition, dermatologists should try to distinguish between anxiety-induced sweating and prJournal Club: Combining Dupilumab and Omalizumab
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combining-dupilumab-and-omalizumab/37872/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, and editorial board member Brad Glick, DO, MPH, FAAD, discuss a recent article about combination therapy with dupilumab and omalizumab for atopic dermatitis. Silva IC, Daher R, Khattri S. Combined use of Omalizumab and dupilumabUnmet Needs in Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37140/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, talks about what he feels are the greatest unmet needs in atopic dermatitis.Biologics in the Treatment Landscape for Atopic Dermatitis Patients
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37144/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, describes how newly available biologics in recent years have impact clinicians’ ability to treat atopicDWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.Red Light vs Blue Light Therapy
https://practicaldermatology.com/series/pdt-in-practice/red-light-vs-blue-light-therapy/26993/Dr. Hamza D. Bhatti, a board-certified dermatologist and dually accredited fellowship-trained Mohs micrographic surgeon and cosmetic dermatologic surgeon, discusses the differences between red light and blue light photodynamic therapy (PDT), the advantages of each, and some off-label uses of PDT.Exosomes 101
https://practicaldermatology.com/conferences/scale-2023/exosomes-101/20192/Exosomes are today's hottest skincare ingredient, and Glynis Ablon, MD, gives viewers the scoop on how and when to use them.Skin Cancer Perceptions, Cimzia for Psoriasis, Eczema and CV Risk
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-skin-cancer-perceptions-cimzia-for-psoriasis-eczema-and-cv-risk/18301/A new national survey, Skin Cancer In America 2018, conducted by Health Union, explores perceptions of patients with skin cancer. Cimzia (certolizumab pegol, UCB) has received FDA approval for treatment of adults with moderate to severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti T